LEVELS OF ANTI-PERTUSSIS ANTIBODIES RELATED TO PROTECTION AFTER HOUSEHOLD EXPOSURE TO BORDETELLA-PERTUSSIS

Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular fi ve-component vaccine, 42.4% for an acellular two-component vaccine and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Log istic regression analyses demonstrated statistically significant corre lations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure s era. Multicomponent pertussis vaccines of proven high efficacy in rece nt Swedish NIAID-sponsored efficacy trials induced higher antibody lev els against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surroga te markers of protection for multicomponent acellular and whole-cell v accines against pertussis. (C) 1998 Elsevier Science Ltd. All rights r eserved.